A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

2012189 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: Annals of Oncology

Volume 23, Issue 11, pp. 2834-2842

Field-Weighted Citation Impact: 10.87